Update on quadrivalent human papillomavirus vaccination and pregnancy outcomes: is contraception advisable?

No authors listed

Editorial

No authors listed. Obstet Gynecol. 2009 Dec.

. 2009 Dec;114(6):1168-1169.

doi: 10.1097/AOG.0b013e3181c479f8.

No abstract available

Comment on

Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine.
Dana A, Buchanan KM, Goss MA, Seminack MM, Shields KE, Korn S, Cunningham ML, Haupt RM. Dana A, et al. Obstet Gynecol. 2009 Dec;114(6):1170-1178. doi: 10.1097/AOG.0b013e3181c2a122. Obstet Gynecol. 2009. PMID: 19935016
Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials.
Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, Saah A, Marino D, Ryan D, Radley D, Zhou H, Haupt RM, Garner EIO; Quadrivalent Human Papillomavirus Vaccine Phase III Investigators. Garland SM, et al. Obstet Gynecol. 2009 Dec;114(6):1179-1188. doi: 10.1097/AOG.0b013e3181c2ca21. Obstet Gynecol. 2009. PMID: 19935017

1. Dana A, Buchanan KM, Gos MA, Seminack MM, Shields KE, Korn S, et al. Pregnancy outcomes from the Pregnancy Registry of the quadrivalent human papillomavirus types 6/11/16/18 vaccine. Obstet Gynecol 2009;114:1170–8.
1. Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. Pregnancy outcomes in the clinical trials of the human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009;114:1179–88.
1. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915–27.